

Tysabri Order Form (natalizumab)

FAX TO: 972.499.9210

PATIENT INFORMATION			
Patient Name:			
DOB: Phone:	Sex:	М	F
DIAGNOSIS & CLINICAL INFORMATION			
ICD 10 Code (Required) G35 Multiple Sclerosis K50.00 Crohn's Disease, Small Intestine K50.10 Crohn's Disease, Large Intestine			n's Disease, Small and Large Intestine n's Disease, Unspecified
Patient Status: New to therapy Continuing therapy (date of last dose)	Weight: Allergie		lb kg Height:
PRESCRIPTION			
Pre-Medications Acetaminophen: 650 mg PO Cetrizine: 10 mg PO Diphenhydramine: 25 mg PO	Famotid Methylp	ine: 2 rednis	nine: 25 mg IVP 0 mg PO olone: 125 mg SIVP
TSYABRI (natalizumab)			
300 mg IV every 4 weeks for 1 year			
Is the patient on any other disease modifying therapy? Yes No Is yes, please note therapy and last dose:			
Adverse Events: In the event of an adverse reaction occurring at a Medix Infusion suite, utilize the Medix Infusion adverse reactions protocol.			
Other Orders:			
REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING AND INSURANCE APPROVAL			
 Signed and completed order Patient's demographic and insurance information Patient's medication list Supporting clinical notes that include any past tried and/or failed therapies, intolerance, benefits, or contraindications to conventional therapy Patient enrolled in TOUCH program; prescriber is a TOUCH 	Supporting/labs diagnostics: Include anti-JCV antibodies test results within last 6 months. Patients who are anti-JCV antibody positive will require documentation from prescriber that risks/benefits have been discussed. Medix Infusion will collect all necessary labs if not included in referral documents		
authorized provider referral documents PRESCRIBER INFORMATION			
Prescriber Name:			
Signature:			
NPI #:			
Supervising Physician (if applicable):			
Address:			
City:			
Contact Name:	Phone:		